Grifols S.A Market Cap ($4.42 Billion)
Market Cap & Net Worth: Grifols S.A (G0FB)
Grifols S.A market cap. Grifols S.A (F:G0FB) has a market capitalization of $4.42 Billion (€3.78 Billion) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #3753 globally and #694 in its home market, demonstrating a 15.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Grifols S.A's stock price €7.50 by its total outstanding shares 680575312 (680.58 Million). Also see G0FB cash flow metrics for how efficiently the company converts equity into cash flow.
Grifols S.A Market Cap History (2015–2026)
Grifols S.A market cap history from 2015 to 2026. Data shows change from $10.40 Billion to $5.97 Billion (-4.67% CAGR). Check Grifols S.A stock quote for real-time trading data and today's change.
Grifols S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Grifols S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore G0FB year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.80x
Grifols S.A's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.04x
Grifols S.A's market cap is 15.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.44 Billion | $4.05 Billion | $545.46 Million | 2.58x | 19.14x |
| 2017 | $13.48 Billion | $4.32 Billion | $662.70 Million | 3.12x | 20.33x |
| 2018 | $11.66 Billion | $4.49 Billion | $596.64 Million | 2.60x | 19.55x |
| 2019 | $16.25 Billion | $5.10 Billion | $625.15 Million | 3.19x | 25.99x |
| 2020 | $11.57 Billion | $5.34 Billion | $708.99 Million | 2.17x | 16.32x |
| 2021 | $7.87 Billion | $4.93 Billion | $182.80 Million | 1.59x | 43.03x |
| 2022 | $6.05 Billion | $6.06 Billion | $208.28 Million | 1.00x | 29.03x |
| 2023 | $7.36 Billion | $6.59 Billion | $42.00 Million | 1.12x | 175.24x |
| 2024 | $5.53 Billion | $7.21 Billion | $157.00 Million | 0.77x | 35.22x |
| 2025 | $6.05 Billion | $7.52 Billion | $402.00 Million | 0.80x | 15.04x |
Competitor Companies of G0FB by Market Capitalization
Companies near Grifols S.A in the global market cap rankings as of November 3, 2026. Also see Grifols S.A balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Grifols S.A by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1410.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $270.56 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $288.84 |
Market Capitalization of Grifols S.A (2015–2026)
Market capitalization of Grifols S.A from 2015 to today. Between 2015 and today, Grifols S.A's market cap moved from $10.40 Billion to $ 5.97 Billion, with a yearly change of -4.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.97 Billion | -1.32% |
| 2025 | €6.05 Billion | +9.35% |
| 2024 | €5.53 Billion | -24.86% |
| 2023 | €7.36 Billion | +21.71% |
| 2022 | €6.05 Billion | -23.12% |
| 2021 | €7.87 Billion | -32.04% |
| 2020 | €11.57 Billion | -28.77% |
| 2019 | €16.25 Billion | +39.31% |
| 2018 | €11.66 Billion | -13.45% |
| 2017 | €13.48 Billion | +29.05% |
| 2016 | €10.44 Billion | +0.43% |
| 2015 | €10.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Grifols S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.42 Billion USD |
| MoneyControl | $4.42 Billion USD |
| MarketWatch | $4.42 Billion USD |
| marketcap.company | $4.42 Billion USD |
| Reuters | $4.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more